{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:32:30Z","timestamp":1791307950173,"version":"4.3.1"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T00:00:00Z","timestamp":1234828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The armamentarium of anti\u2010leukemic drugs has increased substantially since anti\u2010leukemic activities were recently found for a variety of non\u2010classical cytostatic drugs, among them the histone deacetylase (HDAC) inhibitor valproic acid (VPA). This study investigated the effect of VPA on proliferation and apoptosis of human Philadelphia chromosome\u2010positive (Ph+) acute lymphatic (ALL) and chronic myeloid leukemia (CML) cells and on colony formation of human chronic\u2010phase CML progenitor cells. Strong anti\u2010proliferative and pro\u2010apoptotic effects of VPA were observed on human ALL and CML cell lines at concentrations achievable <jats:italic>in vivo.<\/jats:italic> These effects were most pronounced in ALL cell lines as well as in primary ALL cells. Notably, VPA revealed enhanced activity with imatinib mesylate, nilotinib, the farnesyl transferase inhibitor SCH66336, interferon\u2010alpha and cytosine arabinoside. VPA inhibited the growth of colony\u2010forming cells from 12 Ph+ chronic\u2010phase CML patients but also of those from normal healthy controls in a dose\u2010dependent fashion. HDAC\u2010inhibiting activity of VPA was confirmed on ALL and CML cells. In conclusion, VPA, whether alone or in combination with other non\u2010classical anti\u2010leukemic compounds, exerts significant anti\u2010leukemic effects on human ALL and CML cells.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2009.01242.x","type":"journal-article","created":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T15:22:11Z","timestamp":1234884131000},"page":"48-56","source":"Crossref","is-referenced-by-count":23,"title":["Anti\u2010leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells <i>in vitro<\/i>"],"prefix":"10.1111","volume":"83","author":[{"given":"Brigitte","family":"Kircher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hoflehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Haun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nachbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/300765a0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2408149"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/330386a0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200401000-00006"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600634085"},{"key":"e_1_2_5_8_2","first-page":"285","article-title":"The molecular mechanism of HDAC inhibitors in anticancer effects","volume":"3","author":"Bi G","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2675"},{"key":"e_1_2_5_10_2","first-page":"169","article-title":"The histone deacetylase inhibitor suberoylanilide hydoxamic acid down\u2010regulates expression levels of Bcr\u2010abl, c\u2010Myc and HDAC3 in chronic myeloid leukemia cell lines","volume":"15","author":"Xu Y","year":"2005","journal-title":"Int J Mol Med"},{"key":"e_1_2_5_11_2","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of bcr\/abl and induces apoptosis of imatinib mesylate\u2010sensitive or \u2013refractory chronic myelogenous leukemia\u2010blast crisis cells","volume":"63","author":"Nimmanapalli R","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_12_2","first-page":"3637","article-title":"The histone deacetylase inhibitor MS\u2010275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP\/WAF1","volume":"63","author":"Rosato RR","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.24.6969"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.10017"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.09.008"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21725"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702104"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.291.291"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00905.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2726"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1567"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1404"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1399"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403203"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.3.1068"},{"key":"e_1_2_5_26_2","first-page":"219","article-title":"Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR\u2010ABL\u2010positive cells","volume":"2","author":"Nakajima A","year":"2003","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22901"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.003"},{"key":"e_1_2_5_31_2","first-page":"1795","article-title":"Valproic acid and interferon\u2010alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo","volume":"25","author":"Michaelis M","year":"2004","journal-title":"Int J Oncol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.04.018"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4639"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10758"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.009"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22891"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3317"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504248102"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-9000-0"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"e_1_2_5_41_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1124\/mol.59.5.1269","article-title":"Induction of differentiation in F9 cells and activation of peroxisome proliferator\u2010activated receptor \u03b4 by valproic acid and its teratogenic derivatives","volume":"59","author":"Werling U","year":"2001","journal-title":"Mol Pharm"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104309200"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01242.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01242.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:07:20Z","timestamp":1696979240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01242.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01242.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01242.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}